Side-by-side financials for CTMX and LLY. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | CTMX | LLY |
|---|---|---|
| Market cap | - | $1.067 T |
| US-listed rank | - | #11 |
| Revenue (latest FY) | $76.20M | $65.18B |
| Net income (latest FY) | -$17.37M | $20.64B |
| Net margin | -22.8% | 31.7% |
| P/E (trailing FY) | - | 51.7 |
| SEC filings | 773 | 989 |
In their latest fiscal years, CytomX Therapeutics, Inc. reported $76.20M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: CytomX Therapeutics, Inc. and ELI LILLY & Co, or browse the full rankings.